STOK shares saw an increase of 29% today, marking a multi day upwards trend after earnings.

Shares of Stoke Therapeutics Inc (STOK) are trading 29% higher at a price of $21.73 at the time of this writing. The burgeoning biotech company's stock is trading higher, continuing its multi day upward trajectory after a strong earnings report. The RNA-pioneer reported an EPS beat of about $0.05 on -$0.63 , and a revenue beat of $0.18M on $3.2M.

Stoke Therapeutics Inc has been trading between a 52-week high of $33.06 and a 52-week low of $9.55. The stock has a market cap of $851 Million.

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.